10-Q: Vycor Medical Reports Mixed Results in Q2 2024 Amidst Ongoing Financial Challenges

Vycor Medical's Q2 2024 results show a decrease in revenue compared to the same period last year, alongside ongoing concerns about the company's ability to continue as a going concern.

Summary

• Vycor Medical reported a net loss of $40,646 for the six months ended June 30, 2024, and a net loss of $10,038 for the three months ended June 30, 2024.
• The company's revenue decreased to $743,246 for the six months ended June 30, 2024, down from $843,762 in the same period of 2023.
• Vycor Medical's working capital deficiency was $3,663,740 as of June 30, 2024, which includes $3,146,542 in related party liabilities.
• The company's cash balance increased to $119,296 as of June 30, 2024, up from $57,291 at the end of 2023.
• Vycor Medical is executing a plan to reduce cash operating losses and achieved cash operating income for the six months ended June 30, 2024.
• The company's ability to continue as a going concern is in doubt due to ongoing losses and a working capital deficiency.

Sentiment

Score: 3

Explanation: The document indicates significant financial challenges, including declining revenue, net losses, and a substantial working capital deficiency. The company's ability to continue as a going concern is in doubt, and there is uncertainty regarding future funding. While there are some positive aspects, such as the increase in cash balance and the achievement of cash operating income, the overall sentiment is negative due to the significant financial risks and challenges.

Positives

• The company achieved cash operating income for the six months ended June 30, 2024.
• Vycor Medical's cash balance increased to $119,296 as of June 30, 2024, from $57,291 at the end of 2023.
• Gross margin for Vycor Medical was 90% for the six months ended June 30, 2024.
• Gross margin for NovaVision was 94% for the six months ended June 30, 2024.

Negatives

• The company reported a net loss of $40,646 for the six months ended June 30, 2024.
• Vycor Medical's revenue decreased by 12% to $743,246 for the six months ended June 30, 2024.
• The company has a significant working capital deficiency of $3,663,740 as of June 30, 2024.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's operating expenses increased to $664,431 for the six months ended June 30, 2024, from $643,438 in the same period of 2023.
• The company's gross profit decreased to $671,077 for the six months ended June 30, 2024, from $773,166 in the same period of 2023.

Risks

• The company's ability to continue as a going concern is in doubt due to ongoing losses and a working capital deficiency.
• There is uncertainty regarding the extension of a $300,000 term note due on March 31, 2025.
• The company may not have sufficient cash to meet its needs through August 31, 2025, without additional funding.
• There is no guarantee that Fountainhead will continue to provide working capital funding.
• The company may have to delay or curtail development or commercialization of products if adequate funds are not available.
• The company's internal controls are considered ineffective due to the lack of a functioning audit committee with independent members.

Future Outlook

The company is executing a plan to reduce cash operating losses and is exploring various strategic options, including partnerships, licensing, and potential sale of divisions. The company may seek additional equity or debt funding, but there is no assurance that this would be available on acceptable terms or at all.

Management Comments

• Management believes that the material weakness set forth did not have an effect on our financial results.
• Management believes that the lack of a functioning audit committee and the lack of a majority of outside directors on our board of directors, results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in our financial statements in future periods.

Industry Context

The company operates in the medical device industry, with a focus on neurosurgery and vision rehabilitation. The company is facing challenges in revenue growth and profitability, which is not uncommon in the medical device sector, particularly for smaller companies. The company is exploring strategic partnerships and licensing agreements, which is a common strategy for smaller medical device companies to expand their reach and market penetration.

Comparison to Industry Standards

• Vycor Medical's revenue decline of 12% for the six months ended June 30, 2024, is concerning compared to industry standards, where many medical device companies are experiencing growth.
• Companies like Medtronic and Stryker, which are leaders in the medical device industry, have reported positive revenue growth in recent quarters, indicating that Vycor Medical is underperforming its peers.
• The company's working capital deficiency of $3,663,740 is also a significant concern, as many medical device companies maintain a healthy working capital position to support their operations and growth.
• Compared to companies like InMode, which focuses on minimally invasive aesthetic procedures, Vycor Medical's financial performance is significantly weaker.
• The company's reliance on related party funding and the uncertainty surrounding the extension of the EuroAmerican note are also not typical of well-established medical device companies.

Corporate Governance

Legal Proceedings

• As of August 13, 2024, the company was not a party to any material litigation, claim or suit whose outcome could have a material effect on its financial statements.

Related Party Transactions

• Peter Zachariou and David Cantor, directors of the Company, are investment managers of Fountainhead which owned, at June 30, 2024, 62.3 % of the Companys Common Stock and 69.7 % of the Companys Series D Preferred Stock.
• Peter Zachariou owns 0.15 % of the Companys Common Stock and 25.7 % of the Companys Series D Preferred Stock.
• Adrian Liddell, Chairman is a consultant to Fountainhead.
• During each of the six months ended June 30, 2024 and 2023, the Company accrued an aggregate of $162,185 of Preferred D Stock dividends, of which $113,019 was regarding Fountainhead and $41,693 was regarding Peter Zachariou.
• Total accrued Preferred D Stock dividends at June 30, 2024 and December 31, 2023 was $2,432,775 and $2,270,590, respectively, of which $1,695,280 and $1,582,260 respectively, was regarding Fountainhead and $625,394 and $583,701, respectively, was regarding Peter Zachariou.
• During the six months ended June 30, 2024 and 2023 the Company accrued interest on related party loans of $24,872 and $24,644, respectively.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and the uncertainty surrounding its ability to continue as a going concern.
• Employees may be affected by potential delays or curtailment of operations if the company is unable to secure additional funding.
• Customers may experience disruptions in product availability or service if the company's financial situation worsens.
• Suppliers may face increased risk of non-payment or delayed payments due to the company's financial challenges.
• Creditors face increased risk of non-repayment due to the company's financial instability.

Next Steps

• The company will continue to execute on a plan to reduce cash operating losses.
• The company will explore strategic partnerships, licensing agreements, and potential sale of divisions.
• The company may seek additional equity or debt funding.
• The company will continue to work with neuronavigation companies to seek ways to further integrate the VBAS with neuronavigation.

Key Dates

Keywords

Vycor Medical, financial results, medical devices, neurosurgery, NovaVision, rehabilitation therapies, working capital, going concern, revenue, net loss, operating income, cash flow, debt, preferred stock, related party transactions